Apeiron has announced the signing of two transactions as part of the worldwide commercialisation of APN311, an antibody-based immunotherapy in development for the treatment of children suffering from high-risk neuroblastoma
Apeiron announced the signing of license agreements with Medison and Gen Ilac. The two deals grant Medison and Gen Ilac exclusive rights to market and sell APN311 in Israel and Turkey, respectively. These transactions are part of Apeiron’s ongoing activities for worldwide commercialisation of its immunotherapy portfolio against high-risk neuroblastoma.
Hans Loibner, CEO of Apeiron, comments: “Based on very positive clinical data and the advanced development status of APN311 we are actively engaged in discussions with potential partners around the world for commercialisation of this immunotherapy. After a first agreement with Paladin Labs we are pleased to now close these two deals with Medison and Gen Ilac. This represents a further important step in Apeiron’s efforts and commitment to improve therapeutic options for children suffering from life-threatening high-risk neuroblastoma”.
Meir Jakobsohn, Medison’s founder and CEO says: “We are proud of the new agreement with Apeiron that reflects Medison’s continuous ambition to provide breakthrough and lifesaving treatments for today’s most urgent medical needs. One of Medison’s main focuses is providing medications in the field of paediatric oncology, in niches with unmet need. Apeiron’s treatment fits exactly to Medison’s mission”.
Abidin Gülmüs, CEO of Gen Ilac, adds: “We are proud of our reputation as one of Turkey’s leading specialty pharma companies, but even more important to us is the difference we make to the lives of people with life-threatening conditions. We look forward to a successful partnership with Apeiron, together providing oncologists with the opportunity to treat high-risk neuroblastoma patients. We aspire to make APN311 available for Turkish patients as soon as possible”.